First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDaiichi Sankyo
About this trial
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Eligibility criteria
Qualifiers
Sign and date the main Informed Consent Form (ICF).
Has a left ventricular ejection fraction ≥50% by either an echocardiogram or multigated acquisition within 28 days of enrollment.
Has adequate organ function.
Measurable disease based on RECIST V1.1.
Disqualifiers
Has had prior treatment targeting mucin 1 (MUC1) or TA-MUC1.
Has spinal cord compression or clinically active central nervous system metastases.
Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years.
Has a history of noninfectious interstitial lung disease (ILD)/pneumonitis (including suspected one), has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
Trial design
Treatments tested in this trial
- DS-3939a
Treatment groups
540 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov